Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9544593 | 0.79 | OPRL1 (0.50) | PTGDR2 | |
| SCHEMBL17830710 | 0.77 | ALDH1A1 (0.64) | PARK7 | |
| SCHEMBL17830713 | 0.76 | USP2 (0.44) | PTGDR2 | |
| SCHEMBL15156486 | 0.75 | TP53 (0.52) | — | |
| SCHEMBL9541775 | 0.74 | TDP1 (0.51) | — | |
| SCHEMBL2480348 | 0.73 | PTGDR2 (0.76) | PTGDR2 | |
| SCHEMBL12674686 | 0.71 | ALDH1A1 (0.51) | — | |
| SCHEMBL17830745 | 0.71 | ALDH1A1 (0.56) | — | |
| SCHEMBL9543551 | 0.71 | OPRL1 (0.48) | — | |
| SCHEMBL9774461 | 0.70 | TDP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | PTGDR2 2621/4885PARK7 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.